dc.creator | Martínez-Sanz, Javier | es |
dc.creator | Ron, Raquel | es |
dc.creator | Moreno, Elena | es |
dc.creator | Sánchez-Conde, Matilde | es |
dc.creator | Muriel, Alfonso | es |
dc.creator | López Cortés, Luis Fernando | es |
dc.creator | Pineda Vergara, Juan Antonio | es |
dc.creator | Serrano-Villar, Sergio | es |
dc.date.accessioned | 2022-11-08T14:15:48Z | |
dc.date.available | 2022-11-08T14:15:48Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Martínez-Sanz, J., Ron, R., Moreno, E., Sánchez-Conde, M., Muriel, A., López Cortés, L.F.,...,Serrano-Villar, S. (2022). Similar CD4/CD8 Ratio Recovery After Initiation of Dolutegravir Plus Lamivudine Versus Dolutegravir or Bictegravir-Based Three-Drug Regimens in Naive Adults With HIV. Frontiers in Immunology, 13, 873408. https://doi.org/10.3389/fimmu.2022.873408. | |
dc.identifier.issn | 1664-3224 | es |
dc.identifier.uri | https://hdl.handle.net/11441/139124 | |
dc.description.abstract | The initiation of antiretroviral treatment based on a 2-drug regimen (2DR) with
dolutegravir plus lamivudine has demonstrated non-inferior efficacy than dolutegravir-based
three-drug regimens (3DR). We aimed to assess whether the treatment initiation with this 2DR
has a different impact on the CD4/CD8 ratio recovery than INSTI-based 3DR.
Methods: We emulated a target trial using observational data from the Spanish HIV Research
Network cohort (CoRIS). The outcomes of interest were the normalization of the CD4/CD8 ratio
at 48 weeks using three different cutoffs: 0.5, 1.0, and 1.5. We matched each participant who
started 2DR with up to four participants who received 3DR. Subsequently, we fitted generalized
estimating equation (GEE) models and used the Kaplan–Meier method for survival curves.
Results: We included 485, 805, and 924 participants for cutoffs of 0.5, 1.0, and 1.5,
respectively. At 48 weeks, 45% of participants achieved a CD4/CD8 ratio >0.5, 15%
achieved a ratio >1.0, and 6% achieved a ratio >1.5. GEE models yielded a similar risk of
reaching a CD4/CD8 ratio >0.5 (OR 1.00, 95% CI 0.67 - 1.50), CD4/CD8 >1.0 (OR 1.03,
95% CI 0.68 - 1.58), and CD4/CD8 >1.5 (OR 0.86, 95% CI 0.48 - 1.54) between both
treatment strategies. There were no differences between 2DR and 3DR in the incidence
ratio of CD4/CD8 ratio normalization at 0.5, 1.0 and 1.5 cut-offs.
Conclusions: In this large cohort study in people with HIV, ART initiation with dolutegravir
plus lamivudine vs. dolutegravir or bictegravir-based triple antiretroviral therapy showed
no difference in the rates of CD4/CD8 normalization at 48 weeks. | es |
dc.format | application/pdf | es |
dc.format.extent | 6 p. | es |
dc.language.iso | eng | es |
dc.publisher | FRONTIERS MEDIA SA | es |
dc.relation.ispartof | Frontiers in Immunology, 13, 873408. | |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | HIV | es |
dc.subject | Dual therapy | es |
dc.subject | Antiretroviral therapy | es |
dc.subject | CD4/CD8 ratio | es |
dc.subject | Integrase inhibitors | es |
dc.title | Similar CD4/CD8 Ratio Recovery After Initiation of Dolutegravir Plus Lamivudine Versus Dolutegravir or Bictegravir-Based Three-Drug Regimens in Naive Adults With HIV | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.projectID | RD06/006 | es |
dc.relation.projectID | RD12/0017/0018 | es |
dc.relation.projectID | RD16/ 0002/0006 | es |
dc.relation.projectID | AC17/00019 | es |
dc.relation.projectID | PI18/00154 | es |
dc.relation.projectID | COV20/00349 | es |
dc.relation.projectID | ICI20/00058 | es |
dc.relation.publisherversion | https://www.frontiersin.org/articles/10.3389/fimmu.2022.873408/full | es |
dc.identifier.doi | 10.3389/fimmu.2022.873408 | es |
dc.journaltitle | Frontiers in Immunology | es |
dc.publication.volumen | 13 | es |
dc.publication.initialPage | 873408 | es |
dc.contributor.funder | Red Temática de Investigación Cooperativa en Sida | es |
dc.contributor.funder | Instituto de Salud Carlos III | es |
dc.contributor.funder | European Commission (EC). Fondo Europeo de Desarrollo Regional (FEDER) | es |